Tags

Type your tag names separated by a space and hit enter

Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine.
Age Ageing. 2006 Jul; 35(4):365-71.AA

Abstract

BACKGROUND

few studies have analysed the effect of the long-term use of cholinesterase inhibitors (ChEIs) on mortality.

OBJECTIVE

to compare the long-term effects of galantamine and donepezil treatment on the mortality rate in Alzheimer's disease (AD) patients.

DESIGN

a retrospective cohort study.

SETTING AND SUBJECTS

404 patients referred by primary care centres to a Memory Clinic who were diagnosed with probable AD and who were prescribed treatment with donepezil or galantamine.

METHODS

standardised review of the patient's medical records.

RESULTS

14.5% of the patients showed intolerance to the treatment with ChEIs during the first 15 days. Of those patients who initially tolerated the treatment, 18.5% gave it up after a mean duration of 13.36 months and a mean dose of 7.5 mg/day of donepezil or 14.3 mg/day of galantamine. The mean duration of the treatment in patients who did not abandon the treatment was 25.4 months and the mean dose was 8.1 mg/day of donepezil or 20.0 mg/day of galantamine. There were no differences in the mortality rate between patients treated with donepezil or galantamine (13.7 versus 12.2; P = 0.75). The multivariate analysis through binary logistic regression showed that the variables associated with mortality were male gender, older age, heart failure, treatment with antipsychotic drugs and a high score on the Global Deterioration Scale.

CONCLUSIONS

the duration and the dose of donepezil or galantamine are not related to an increase in mortality. The related variables were advanced age, the severity of the dementia, being male, heart failure and treatment with antipsychotic drugs.

Authors+Show Affiliations

Research Unit, Institut d'Assistència Sanitaria, C/Dr. Castany s/n, Salt 17190 (Girona), Spain. recerca@ias.scs.esNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

16788079

Citation

López-Pousa, Secundino, et al. "Comparative Analysis of Mortality in Patients With Alzheimer's Disease Treated With Donepezil or Galantamine." Age and Ageing, vol. 35, no. 4, 2006, pp. 365-71.
López-Pousa S, Olmo JG, Franch JV, et al. Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine. Age Ageing. 2006;35(4):365-71.
López-Pousa, S., Olmo, J. G., Franch, J. V., Estrada, A. T., Cors, O. S., Nierga, I. P., & Gelada-Batlle, E. (2006). Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine. Age and Ageing, 35(4), 365-71.
López-Pousa S, et al. Comparative Analysis of Mortality in Patients With Alzheimer's Disease Treated With Donepezil or Galantamine. Age Ageing. 2006;35(4):365-71. PubMed PMID: 16788079.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine. AU - López-Pousa,Secundino, AU - Olmo,Josep Garre, AU - Franch,Joan Vilalta, AU - Estrada,Antoni Turon, AU - Cors,Olga Soler, AU - Nierga,Imma Pericot, AU - Gelada-Batlle,Esther, PY - 2006/6/22/pubmed PY - 2007/10/20/medline PY - 2006/6/22/entrez SP - 365 EP - 71 JF - Age and ageing JO - Age Ageing VL - 35 IS - 4 N2 - BACKGROUND: few studies have analysed the effect of the long-term use of cholinesterase inhibitors (ChEIs) on mortality. OBJECTIVE: to compare the long-term effects of galantamine and donepezil treatment on the mortality rate in Alzheimer's disease (AD) patients. DESIGN: a retrospective cohort study. SETTING AND SUBJECTS: 404 patients referred by primary care centres to a Memory Clinic who were diagnosed with probable AD and who were prescribed treatment with donepezil or galantamine. METHODS: standardised review of the patient's medical records. RESULTS: 14.5% of the patients showed intolerance to the treatment with ChEIs during the first 15 days. Of those patients who initially tolerated the treatment, 18.5% gave it up after a mean duration of 13.36 months and a mean dose of 7.5 mg/day of donepezil or 14.3 mg/day of galantamine. The mean duration of the treatment in patients who did not abandon the treatment was 25.4 months and the mean dose was 8.1 mg/day of donepezil or 20.0 mg/day of galantamine. There were no differences in the mortality rate between patients treated with donepezil or galantamine (13.7 versus 12.2; P = 0.75). The multivariate analysis through binary logistic regression showed that the variables associated with mortality were male gender, older age, heart failure, treatment with antipsychotic drugs and a high score on the Global Deterioration Scale. CONCLUSIONS: the duration and the dose of donepezil or galantamine are not related to an increase in mortality. The related variables were advanced age, the severity of the dementia, being male, heart failure and treatment with antipsychotic drugs. SN - 0002-0729 UR - https://www.unboundmedicine.com/medline/citation/16788079/Comparative_analysis_of_mortality_in_patients_with_Alzheimer's_disease_treated_with_donepezil_or_galantamine_ L2 - https://academic.oup.com/ageing/article-lookup/doi/10.1093/ageing/afj083 DB - PRIME DP - Unbound Medicine ER -